Home -> Law Blog Directory -> Intellectual Property Law Blogs -> Two-Seventy-One Patent Blog
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Intellectual Property Law
: Two-Seventy-One Patent BlogBombshell Study: Heavily Litigated NPE Patents Overwhelmingly Lose at Trial
By Peter Zura
John Allison, Mark Lemley and Joshua Walker recently took on the task of identifying every patent that was litigated eight or more times between 2000 and February 2009, including cases still pending, and compared the outcomes of the cases against patents that were litigated only once. In the course of their analysis, they found 106 such patents, which have been litigated in a total of 2,987 different patent assertions in 478 different cases, often against multiple defendants.
What did they find? Serial patent litigants, and particularly NPE's (aka "trolls"), for a lack of a better phrase, "get creamed" when they go to trial:
[T]o our great surprise, we find that the willingness of these patentees to litigate their cases to judgment is a mistake. Far from being stronger than other litigated patents, the most--litigated patents that go to judgment are far more likely to be held invalid or not infringed. The differences are dramatic. Once-litigated patents win in court almost 50% of the time, while the most-litigated ? and putatively most valuable ? patents win in court only 10.7% of the time.The results are equally striking for patents owned by non-practicing entities (NPEs), and for software patents. NPEs and software patentees overwhelmingly lose their cases, even with patents that they litigate again and again. Software patentees win only 12.9% of their cases, while NPEs win only 9.2%.[S]tatistical tests bear this out. We compare the proportion of win rates, testing the null hypothesis that there is no difference between the most-litigated and once-litigated patent outcomes. We test the proportions in several ways, both including and excluding settlements in the denominator of decided cases, and both including and excluding default judgments as plaintiff wins. No matter which test we use, the differences are highly statistically significant ? the most-litigated patentees were more likely to lose.
Considering only the patents themselves, the proportions of initial ownership by large and small entities are almost equal in the most- and once-litigated data sets: 53.5% of most-litigated patents and 47.8% of once-litigated patents were issued to large entities. The picture is quite different, however, when one looks at the proportion of actual assertions in litigation, where large entities account for a surprisingly small percentage of the most-litigated patents. Because small entities are disproportionately represented in the actual litigation of most-litigated patents . . . patents that were initially issued to large entities represent only 22.4% of the assertions in the most-litigated group, compared to 47.8% of the once-litigated group.[W]hen the cases do not settle, large patent plaintiffs are significantly more likely than small ones to win, without regard to how the data are sliced. When we combine the two data sets, large entity plaintiffs win 53.1% of the cases decided on the merits (55.9% if default judgments are included), while small entity plaintiffs win only 12.3% of their cases (23.1% if default judgments are included).
We designed this study to explore the effects of repeat play on litigation behavior, contributing to a literature on the economics of civil procedure as well as the substance of patent law. But what we found was dramatic and unexpected: The patents and patentees that occupy the most time and attention in court and in public policy debates ? the very patents that economists consider the most valuable ? are astonishingly weak. Non-practicing entities and software patentees almost never win their cases. That may be a good thing, if you believe that most software patents are bad or that NPEs are bad for society. But it certainly means that the patent system is wasting more of its time than expected dealing with weak patents. And it also suggests that both our measures of patent value and our theories of litigation behavior need some serious reconsideration.
Full post as published by Two-Seventy-One Patent Blog on September 23, 2010 (boomark / email).
Cipro
The FDA is seeking to add black box warnings of the risk of tendon rupture associated with Cipro and Levaquin.
The ruptures can involve Achilles tendon, shoulder, hand, bicep or thumb tendons, and is especially increased in patients older than 60, or people who have received kidney, heart or lung transplants, as well as people on steroid therapy...
Procrit
Associated with Death in Stroke Study
Xigris
Study Prompts FDA Safety Review
BPA
New Study Shows Link to Diabetes and Heart Disease
New Study Links Cell Phone Radiation to Increased Health Risks
Cell Phone Radiation Is Your Phone Toxic?

Patent Litigation Statistics: Number of Patents Being Litigated
BOMBSHELL STUDY: At last, the truth is out men do work harder than women, says Neil Lyndon. A
BOMBSHELL STUDY: Oral Sex Is In: High school boys, rejoice! Perhaps it was Clintons infamous se
BOMBSHELL STUDY: Teen Sex Not Bad For School Performance.
Design Patents: No longer the Province of Individual Inventors








